Leerink Partnrs boosted their FY2024 earnings per share (EPS) estimates for CRISPR Therapeutics in a note issued to investors ...

CRISPR Therapeutics AG (NASDAQ:CRSP – Get Free Report) has earned a consensus recommendation of “Hold” from the nineteen ...

CRISPR Therapeutics AG (CRSP) closed at $43.42 in the latest trading session, marking a -1.83% move from the prior day. The stock trailed the S&P 500, which registered a daily loss of 0.29%. Meanwhile ...

MaxCyte Inc. (NASDAQ: MXCT) is a global developer of next-generation cell therapies. They provide crucial technology for cell ...

RFK Jr.’s portfolio, made public through a January 21 disclosure to the Office of Government Ethics, includes a $5,000,000 ...

Stock analysts at Cantor Fitzgerald issued their FY2025 earnings per share (EPS) estimates for shares of CRISPR Therapeutics ...

Financial disclosures released ahead of confirmation hearings for Robert F. Kennedy Jr., President Trump’s nominee to lead the health ...

Arkadios Wealth Advisors lifted its position in shares of CRISPR Therapeutics AG (NASDAQ:CRSP – Free Report) by 7.7% during the 4th quarter, according to the company in its most recent Form 13F filing ...

An Alphabet-backed startup is poised to begin clinical trials of its first artificial intelligence-designed drug by year-end.

Bullish option flow detected in Crispr Therapeutics (CRSP) with 3,734 calls trading, 1.3x expected, and implied vol increasing almost 4 points ...

CRISPR Therapeutics AG (NASDAQ:CRSP), a leading biotechnology company specializing in gene-based medicines with a market capitalization of $3.45 billion, stands at a critical juncture as it navigates ...

In this article, we are going to take a look at where CRISPR Therapeutics AG (NASDAQ:CRSP) stands against other biotech ...